Questions Answered

New England Gynecology Plus PLLC is a physician-led professional organization founded by Dr. Jimmy Belotte, MD, PhD, MBA, FACOG. It operates across two segments: an active healthcare consulting and advisory practice, and a care delivery platform (OBGYN and primary care) currently in development with an anticipated patient-facing launch in 2027.

Dr. Belotte is a board-certified OB-GYN holding an MD, PhD, and MBA, and is a Fellow of the American College of Obstetricians and Gynecologists (FACOG). He has built a career at the intersection of medicine, capital markets, and organizational strategy — advising health systems, biotech companies, private equity firms, and C-suite leadership teams. He is the Founder and Managing Principal of NEG Plus PLLC. Learn more on the Leadership page.

NEG Plus PLLC's consulting practice serves clients nationally and internationally. The care delivery practice will be regionally anchored in New England, with site selection currently underway for the anticipated 2027 launch.

For consulting and advisory engagements, reach us at consulting@negplushealth.com. For speaking inquiries, use the same address with the subject line "Speaking Engagement Inquiry." For care delivery interest, use the Interest Registration form.

We work with a wide range of organizations including health systems and hospital networks, biotech and pharmaceutical companies, medical device manufacturers, private equity and venture capital firms, academic medical centers, payers and managed care organizations, digital health companies, and C-suite and board-level leadership teams. We specialize in women's health, oncology, and life sciences.

We offer flexible engagement structures including project-based advisory, retained strategic counsel, fractional Chief Medical Officer (CMO) or Chief Strategy Officer (CSO) arrangements, expert witness and litigation support, and speaking and executive education. Engagements are structured to fit the client's specific needs and timeline. See our Engagement Models and Rates & Terms for details.

Yes. We regularly work with early-stage biotech, MedTech, and digital health companies — from concept validation and pre-clinical strategy through IND/IDE filing, clinical trial design, FDA submission, and commercial launch. Our life sciences advisory spans the full development continuum.

Fees vary by engagement type, scope, and duration. We offer project-based, retainer, and hourly structures. Contact us at consulting@negplushealth.com for a confidential discussion of your needs and a tailored proposal.

The care delivery platform — comprising OBGYN and Women's Health (led by Dr. Belotte) and Primary Care (led by Dr. Mitchell Alexis) — is anticipated to launch in 2027. Site selection, credentialing, and service design are actively underway. Register your interest to receive priority notification when we open.

The practice will offer comprehensive OBGYN and Women's Health services including well-woman care, gynecologic surgery (minimally invasive), obstetrics, menopause management, cervical dysplasia management, fibroid treatment, and gynecologic oncology referrals — alongside a full-spectrum primary care service line. Details are on the Care Delivery page.

Insurance and coverage details are being finalized as part of the practice design. We are committed to broad access. Specific payer information will be shared as the 2027 launch approaches. Register your interest and we'll keep you updated.

The care delivery practice is not yet open to patients — it is scheduled to launch in 2027. In the meantime, you can register your interest at care-delivery.html to receive early access and priority scheduling when we open.

Yes. Dr. Belotte actively accepts keynote, grand rounds, CME, panel, and executive education engagements. He speaks on women's health strategy, gynecologic oncology, physician leadership, the convergence of medicine and capital markets, life sciences commercialization, and healthcare innovation. Contact consulting@negplushealth.com to inquire.

Dr. Belotte is available for keynote addresses, grand rounds presentations, CME-accredited lectures, panel discussions, fireside chats, faculty and leadership development workshops, executive education sessions, and podcast or media appearances. Both in-person and virtual formats are available.

Yes. Dr. Belotte can deliver content eligible for Continuing Medical Education (CME) credit in partnership with your accreditation provider. Topics spanning gynecologic oncology, minimally invasive surgery, and women's health management are particularly well-suited for CME programming.

We advise across the full drug development continuum: target identification and concept validation, pre-clinical strategy, IND filing and Phase I–III clinical trial design, FDA regulatory strategy and NDA/BLA submission, commercial launch planning, and post-market lifecycle management. Both small molecule and biologics programs are within our scope.

Yes. Our medical device advisory covers concept and feasibility, design verification and validation (V&V), 510(k) and PMA regulatory pathways, De Novo classification, clinical evidence strategy, reimbursement (CPT/HCPCS coding and CMS coverage), commercial launch, and post-market surveillance. See our Device Development section for the full pipeline.

Yes. NEG Plus PLLC advises on combination product strategy — programs that span both drug and device regulatory frameworks. We help clients navigate the FDA's Office of Combination Products (OCP), determine lead center designation, and develop integrated regulatory and clinical evidence strategies.